Industry News
Pharmaceutical Industry News
As a key player in the automated…
As a key player in the automated cell therapy manufacturing space grapples with a recent setback, another is making waves with a major commercial pact.
The rare disease biotech announced…
The rare disease biotech announced that it would discontinue efforts to develop Voxzogo for children with Noonan syndrome, a genetic growth disorder that can affect height, facial features and the heart.
The Fierce Pharma Marketing Awards…
The Fierce Pharma Marketing Awards celebrated winners across 20 different categories, with GSK, Novartis, argenx and more taking home trophies.
In a deal that allows Sanofi to…
In a deal that allows Sanofi to shed assets wrapped up in mature products, German drugmaker Cheplapharm will take over 20 medicines and three manufacturing sites from Sanofi. In exchange, Sanofi is picking up a
AbbVie has partnered with the PGA…
AbbVie has partnered with the PGA Tour and the 2026 Presidents Cup, teeing up the “Birdies for Brain Health” initiative to funnel cash to six patient advocacy organizations.
The FDA has approved the…
The FDA has approved the industry’s first radioligand equivalent in Curium’s lutetium Lu 177 dotatate injection, Bexlutry, after a court cleared the Boston company of all patent claims brought by Novartis.
Lindsey Vonn knows more than most…
Lindsey Vonn knows more than most about pain. Spending years training as an elite alpine ski racer puts enough pressure on your body, but Vonn’s injuries and her major crash earlier this year that nearly
The Escalating Warnings About A.I., and the Rise of a Deadly New Street Drug
Plus, the man who went to space — and never wanted to go back.
As trial complexity grows, agentic…
As trial complexity grows, agentic AI is emerging as a new model for connecting workflows and accelerating execution.
Shionogi is stepping up promotion…
Shionogi is stepping up promotion of COVID-19 drug Xocova, working with The Bloc on an omnichannel campaign designed to encourage people to contact their healthcare professional after being exposed to the virus.
The injectable monoclonal antibody…
The injectable monoclonal antibody is the first to treat muscle atrophy in patients with SMA, according to the FDA.
GSK is consolidating two of its…
GSK is consolidating two of its influenza vaccine manufacturing sites into one, leaving hundreds of jobs at risk.
As Novo Nordisk continues its epic…
As Novo Nordisk continues its epic battle with Eli Lilly for market share in the increasingly competitive obesity and diabetes space, Novo is launching a major rebranding of its business, its logo and its name.
Healthcare marketing and comms…
Healthcare marketing and comms agency, Deerfield Group, is creating a new model for growth while making a series of appointments and promotions to help bolster its plans.
GSK is advancing its inaugural…
GSK is advancing its inaugural lung cancer asset, Jideytro, toward a landmark first-line FDA approval, aided by an unprecedented complete response rate.
Etcamah now joins Roche’s rival…
Etcamah now joins Roche’s rival oral SERD, giredestrant, in missing the mark in first-line HR+/HER2- breast cancer, spelling trouble for others’ efforts in the same setting.
How Did a Heart Drug With So Much Promise Fall So Flat?
Cardiologists are struggling to figure out why a drug that should have prevented heart attacks didn’t work at all.
Newly revealed global phase 3 data…
Newly revealed global phase 3 data from Merck and Gilead’s failed Trodelvy first-line non-small cell lung cancer trial could reignite the question around translating Chinese data to the West.
Following formal sign-off from the…
Following formal sign-off from the FDA, Handa Pharmaceuticals’ branded drug reformulation strategy has paid off for a third time.
A preliminary 15% higher death…
A preliminary 15% higher death risk in a phase 3 trial threatens to thwart AstraZeneca and Daiichi Sankyo’s bid to establish their star ADC Enhertu as a first-line treatment for patients with HER2-mutant non-small cell